Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2-Characteristics of Intermediates and Final Product.
Elzbieta Lachert, Joanna Lasocka, Artur Bielawski, Ewa Sulkowska, Katarzyna Guz, Krzysztof Pyrc, Agnieszka Dabrowska, Agata Wawryniuk-Malmon, Magdalena Letowska, Krzysztof Tomasiewicz and 1 more
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 3 institutions in 1 country.
Elzbieta LachertDepartment of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14 Str., 02-776 Warsaw, Poland.
Joanna LasockaDepartment of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14 Str., 02-776 Warsaw, Poland.ORCID 0000-0002-8864-5422
Artur BielawskiBiomed Company, Uniwersytecka 10 Str., 20-029 Lublin, Poland.
Ewa SulkowskaDepartment of Virology, Institute of Hematology and Transfusion Medicine, Chocimska 5 Str., 00-957 Warsaw, Poland.
Katarzyna GuzDepartment of Immunohematology and Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Chocimska 5 Str., 00-957 Warsaw, Poland.
Krzysztof PyrcVirogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A Str., 30-387 Krakow, Poland.ORCID 0000-0002-3867-7688
Agnieszka DabrowskaVirogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A Str., 30-387 Krakow, Poland.ORCID 0000-0003-1499-4950
Magdalena LetowskaDepartment of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14 Str., 02-776 Warsaw, Poland.
Krzysztof TomasiewiczDepartment of Infectious Diseases, Medical University of Lublin, Stanislawa Staszica 16 Str., 20-081 Lublin, Poland.
Piotr GrabarczykDepartment of Virology, Institute of Hematology and Transfusion Medicine, Chocimska 5 Str., 00-957 Warsaw, Poland.
Instytut Hematologii i Transfuzjologi · PLJagiellonian University · PLMedical University of Lublin · PL
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
This study aims to characterize the intermediates, and the final product (FP) obtained during the production of human intramuscular hyperimmune gamma globulin anti-SARS-CoV-2 (hIHGG anti-SARS-CoV-2) and to determine its stability.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2-Characteristics of Intermediates and Final Product. · full record | OpenQuestion